- Home
- CHN vs CLLS Comparison
CHN vs CLLS Comparison
Compare CHN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- CLLS
- Stock Information
- Founded
- CHN 1992
- CLLS 1999
- Country
- CHN United States
- CLLS France
- Employees
- CHN N/A
- CLLS N/A
- Industry
- CHN Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- CHN Finance
- CLLS Health Care
- Exchange
- CHN Nasdaq
- CLLS Nasdaq
- Market Cap
- CHN 153.9M
- CLLS 143.4M
- IPO Year
- CHN N/A
- CLLS 2007
- Fundamental
- Price
- CHN $15.87
- CLLS $2.60
- Analyst Decision
- CHN
- CLLS Buy
- Analyst Count
- CHN 0
- CLLS 1
- Target Price
- CHN N/A
- CLLS $4.00
- AVG Volume (30 Days)
- CHN 31.8K
- CLLS 354.9K
- Earning Date
- CHN 01-01-0001
- CLLS 08-04-2025
- Dividend Yield
- CHN 0.19%
- CLLS N/A
- EPS Growth
- CHN N/A
- CLLS N/A
- EPS
- CHN N/A
- CLLS N/A
- Revenue
- CHN N/A
- CLLS $63,438,000.00
- Revenue This Year
- CHN N/A
- CLLS N/A
- Revenue Next Year
- CHN N/A
- CLLS $4.90
- P/E Ratio
- CHN N/A
- CLLS N/A
- Revenue Growth
- CHN N/A
- CLLS 223.09
- 52 Week Low
- CHN $9.00
- CLLS $1.10
- 52 Week High
- CHN $12.98
- CLLS $3.24
- Technical
- Relative Strength Index (RSI)
- CHN 64.58
- CLLS 57.22
- Support Level
- CHN $15.40
- CLLS $2.51
- Resistance Level
- CHN $16.06
- CLLS $2.81
- Average True Range (ATR)
- CHN 0.20
- CLLS 0.32
- MACD
- CHN -0.07
- CLLS -0.00
- Stochastic Oscillator
- CHN 46.53
- CLLS 55.86
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.